BCL6 Inhibition Ameliorates Ruxolitinib Resistance in CRLF2-Rearranged Acute Lymphoblastic Leukemia

To better understand the mechanisms underlying the insufficient efficacy of JAK inhibition, the authors explored gene expression changes upon treatment with a JAK1/2 inhibitor and revealed BCL6 elevation as one such mechanism.